Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer

Urol Oncol. 2005 Nov-Dec;23(6):423-30. doi: 10.1016/j.urolonc.2005.06.007.

Abstract

Increased serum tumor markers after cisplatin-based chemotherapy have usually been considered a contraindication to surgery because of the presence of persistent active germ cell elements. However, a select population of patients with elevated serum tumor markers have undergone post-chemotherapy retroperitoneal lymph node dissection (RPLND) with curative intent. We evaluated the role of surgery to resect retroperitoneal-only marker positive tumor. Long-term survival was observed in 50% of patients. Residual germ cell cancer was identified in 50% of patients, with a third alive at 5 years with no observed benefit from adjuvant chemotherapy. Select patients with increased tumor markers after chemotherapy are cured with surgery.

MeSH terms

  • Biomarkers, Tumor / blood
  • Chemotherapy, Adjuvant
  • Humans
  • Indiana
  • Lymph Node Excision*
  • Lymph Nodes / surgery
  • Neoplasm Staging
  • Neoplasms, Germ Cell and Embryonal / blood
  • Neoplasms, Germ Cell and Embryonal / drug therapy*
  • Neoplasms, Germ Cell and Embryonal / pathology
  • Neoplasms, Germ Cell and Embryonal / surgery*
  • Patient Selection
  • Prognosis
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biomarkers, Tumor